Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pharma Foods International Co., Ltd. (2929.T)
JPY603.00
+4.00 (+0.67%)
JP JPX Healthcare Drug Manufacturers - Specialty & Generic
Address
1-49 Goryo-Ohara 615-8245
Kyoto, JP
Kyoto, JP
CEO
Mu Jo Kim
Website
pharmafoods.co.jp
IPO
2006-06-12
ISIN JP3802310007
Description
Pharma Foods International Co., Ltd. is a Japanese enterprise dedicated to the research, development, and commercialization of ingredients for functional foods. Its diverse product portfolio features items such as Pharma-GABA, Bonepep, Ovopron (a specific egg yolk globulin), Delicious Catechin, RunPep, and enriched Folic Acid Egg. Additionally, the company offers iHA, a compound recognized for stimulating the body's hyaluronic acid production. Furthermore, Pharma Foods International Co., Ltd. has entered into a licensing arrangement with Mitsubishi Tanabe Pharma Corporation for a novel therapeutic antibody designed to combat autoimmune conditions. The firm was founded in 1997 and maintains its corporate headquarters in Kyoto, Japan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY603.00
+4.00 (+0.67%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
195.1K
Beta
0.89
Float Shares
19.51M
Free Float %
67.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.55% | -15.52% | -15.78% | -8.80% | -21.43% | -19.07% | -42.72% | -71.19% | -81.07% | +28.03% | -18.33% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
603.00
DCF (Unlevered)
3,129.84
+419.0%
DCF (Levered)
2,772.62
+359.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.67
Grey zone
Piotroski F-Score
6 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+5.0% Q2'26: -5.0% (vs Q2'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-88.6% Q2'26: +156.5% (vs Q2'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-3.2% Q2'26: -5.6% (vs Q2'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+3.6% Q2'26: +5.8% (vs Q2'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+9.5% ★ Q2'26: +17.2% (vs Q2'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+1.1% Q2'26: 0.0% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×4.01× Q2'26: 3.83× (vs Q2'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jul 2016 actual |
Jul 2017 actual |
Jul 2018 actual |
Jul 2019 actual |
Jul 2020 actual |
Jul 2021 actual |
Jul 2022 actual |
Jul 2023 actual |
Jul 2026 1 Rev. Ana. 1 EPS Ana. |
Jul 2027 1 Rev. Ana. 1 EPS Ana. |
Jul 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.46B
est: 3.41B (+1.6%)
|
4.72B
est: 4.68B (+0.9%)
|
7.94B
est: 7.75B (+2.5%)
|
10.53B
est: 10.33B (+2.0%)
|
15.35B
est: 14.90B (+3.0%)
|
46.75B
est: 46.10B (+1.4%)
|
60.19B
est: 60.50B (-0.5%)
|
68.57B
est: 67.00B (+2.3%)
|
67.00B
67.00B – 67.00B
+0.0% YoY
|
70.00B
70.00B – 70.00B
+4.5% YoY
|
74.00B
74.00B – 74.00B
+5.7% YoY
|
| EBITDA |
-2.98M
est: 249.04M (-101.2%)
|
165.60M
est: 342.30M (-51.6%)
|
315.73M
est: 566.84M (-44.3%)
|
672.92M
est: 755.54M (-10.9%)
|
953.36M
est: 1.09B (-12.5%)
|
5.86B
est: 3.37B (+73.6%)
|
1.60B
est: 4.42B (-63.8%)
|
4.16B
est: 4.90B (-15.2%)
|
4.79B
4.79B – 4.79B
-2.2% YoY
|
5.01B
5.01B – 5.01B
+4.5% YoY
|
5.29B
5.29B – 5.29B
+5.7% YoY
|
| EBIT |
-46.35M
est: 216.97M (-121.4%)
|
89.44M
est: 298.21M (-70.0%)
|
226.59M
est: 493.84M (-54.1%)
|
581.39M
est: 658.24M (-11.7%)
|
801.51M
est: 949.44M (-15.6%)
|
5.67B
est: 2.94B (+93.2%)
|
1.08B
est: 3.86B (-72.0%)
|
3.61B
est: 4.27B (-15.4%)
|
4.16B
4.16B – 4.16B
-2.5% YoY
|
4.35B
4.35B – 4.35B
+4.5% YoY
|
4.60B
4.60B – 4.60B
+5.7% YoY
|
| Net Income |
25.90M
est: 28.74M (-9.9%)
|
101.31M
est: 91.98M (+10.1%)
|
313.66M
est: 149.46M (+109.9%)
|
499.85M
est: 376.53M (+32.8%)
|
690.95M
est: 574.85M (+20.2%)
|
3.84B
est: 3.27B (+17.6%)
|
-374.00M
est: 4.05B (-109.2%)
|
3.08B
est: 4.45B (-30.8%)
|
1.48B
1.48B – 1.48B
-66.7% YoY
|
1.63B
1.63B – 1.63B
+10.1% YoY
|
2.08B
2.08B – 2.08B
+27.3% YoY
|
| SGA |
2.19B
est: 2.32B (-5.7%)
|
3.37B
est: 3.20B (+5.3%)
|
5.81B
est: 5.29B (+9.9%)
|
7.60B
est: 7.05B (+7.8%)
|
10.90B
est: 10.17B (+7.1%)
|
33.49B
est: 31.47B (+6.4%)
|
46.21B
est: 41.30B (+11.9%)
|
50.76B
est: 45.74B (+11.0%)
|
48.99B
48.99B – 48.99B
+7.1% YoY
|
51.19B
51.19B – 51.19B
+4.5% YoY
|
54.11B
54.11B – 54.11B
+5.7% YoY
|
| EPS |
0.89
est: 1.00 (-11.0%)
|
3.49
est: 3.20 (+9.1%)
|
10.80
est: 5.20 (+107.7%)
|
17.21
est: 13.10 (+31.4%)
|
23.79
est: 20.00 (+19.0%)
|
132.21
est: 113.60 (+16.4%)
|
-12.89
est: 141.00 (-109.1%)
|
106.70
est: 154.80 (-31.1%)
|
51.60
51.60 – 51.60
-66.7% YoY
|
56.80
56.80 – 56.80
+10.1% YoY
|
72.30
72.30 – 72.30
+27.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-11 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-06-10 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-06-09 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-06-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-06-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-06-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-06-03 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-06-02 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-06-01 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-26 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-25 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-18 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-15 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-4.31B
OE per share TTM
-148.97
Owner's Yield
-27.39%
Maintenance CapEx ratio
109.94%
Maint CapEx / Avg PPE
6.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 7 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares International Small-Cap Equity Factor ETF ISCF | 0.04% | 277.1K | 0.24% |
| 2 | State Street SPDR S&P International Small Cap ETF GWX | 0.01% | 53.2K | 0.40% |
| 3 | State Street SPDR Portfolio Developed World ex-US ETF SPDW | 0.00% | 642.6K | 0.03% |
| 4 | iShares Core TOPIX ETF 1475.T | 0.00% | 243.4K | 0.05% |
| 5 | Amundi Japan TOPIX II UCITS ETF EUR Dist JPNU.L | 0.00% | 6.8K | 0.45% |
| 6 | Dimensional - International Small Cap ETF DFIS | 0.00% | 14.5K | 0.39% |
| 7 | Dimensional - International Core Equity Market ETF DFAI | 0.00% | — | 0.18% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
3.69M
Shares Outstanding
29.04M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hirotaka Higashiyama | Director of Management Department & Director | — | male |
| Kazuyuki Masuda | Senior MD, Group Mgmt Head & Mail Order Business, President of Pharma Foods Communication & Director | — | male |
| Kosuke Torio | Executive Officer & Director | — | male |
| Masao Nawano | Vice President of R&D Division & Director | — | male |
| Mu Jo Kim | Chief Executive Officer, President & Representative Director | — | male |
| Yong-il Kim | Director of Research & Development and Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2929.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
